Recursion Pharmaceuticals, Inc. RXRX Business Segments — Income Tax Expense (Benefit)

Similar metrics at other companies

ELFReportable Segment — Income Tax Expense (Benefit)

$14.49M+60.6%

GRALReportable Segment — Income Tax Expense (Benefit)

-$34.34M+14.6%

SNDAReportable Segment — Income Tax Expense (Benefit)

$208K+177%

CENXReportable Segment — Income Tax Expense (Benefit)

$1.8M+12.5%

LOGIReportable Segment — Income Tax Expense (Benefit)

$6.39M—

LUNRReportable Segment — Income tax expense (benefit)

$2K—

Questions, answered.

What is Recursion Pharmaceuticals, Inc.'s business segments — income tax expense (benefit)?

Recursion Pharmaceuticals, Inc. (RXRX) reported business segments — income tax expense (benefit) of -$4.6M in Q1 2026.

How has Recursion Pharmaceuticals, Inc.'s business segments — income tax expense (benefit) changed year-over-year?

Recursion Pharmaceuticals, Inc.'s business segments — income tax expense (benefit) decreased by 2813.9% year-over-year, from -$158K to -$4.6M.

What does business segments — income tax expense (benefit) mean?

This metric represents the total income tax provision or benefit allocated to the specific business segment during the reporting period. It reflects the tax impact of the segment's operational results, accounting for jurisdictional tax laws and deferred tax adjustments. Investors use this to understand the tax efficiency and fiscal obligations associated with the segment's distinct business activities.